AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9609375 — intervention group
Group type: COMPARATOR
Intervention: Nonresorbable barrier membrane
Number of subjects: 10
Study 9609375 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier-treated sites with 10% or less bacterial pathogens and free of HCMV and EBV‐1
Number of subjects: 10
Study 9609375 — intervention group
Group type: COMPARATOR
Intervention: Barrier-treated sites with more than 10% bacterial pathogens and/or test viruses
Number of subjects: 10
Study 7978177 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 8
Study 7978177 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone anesthesia
Number of subjects: 8
Study 3071871 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic haemostatic injection with absolute alcohol (Asaki's method)
Number of subjects: 80
Study 3071871 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (blood transfusions, antacids, cimetidine, pirenzepine)
Number of subjects: 80
Study 3071871 — intervention group
Group type: COMPARATOR
Intervention: Postoperative mortality
Number of subjects: 80
Study 31108918 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative telomere length (RTL)
Number of subjects: 4944
Study 27922030 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg, before bedtime)
Number of subjects: 228
Study 27922030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (before bedtime)
Number of subjects: 228
Study 25524481 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity bone cement (group H)
Number of subjects: 32
Study 25524481 — intervention group
Group type: COMPARATOR
Intervention: Low viscosity bone cement (group L)
Number of subjects: 32
Study 22803642 — intervention group
Group type: COMPARATOR
Intervention: TAK-683 (0.01-2.0 mg)
Number of subjects: 60
Study 22803642 — intervention group
Group type: COMPARATOR
Intervention: TAK-683 (0.03-1.0 mg on day 1, followed by 0.01-2.0 mg continuous infusion on days 2-13)
Number of subjects: 60
Study 22803642 — intervention group
Group type: COMPARATOR
Intervention: TAK-683 (2.0 mg day(-1) continuous dosing)
Number of subjects: 60
Study 22803642 — intervention group
Group type: COMPARATOR
Intervention: TAK-683 continuous dosing
Number of subjects: 60
Study 21397402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 4.5g per night
Number of subjects: 548
Study 21397402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 6g per night
Number of subjects: 548
Study 18278611 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART users
Number of subjects: 179
Study 18278611 — intervention group
Group type: COMPARATOR
Intervention: HAART use
Number of subjects: 179
Study 16447105 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (2.5 mg/kg intramuscularly every 12 h for 7 days)
Number of subjects: 65
Study 16447105 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg orally for adults and 2.2 mg/kg orally for children every 12 h for 7 days)
Number of subjects: 65
Study 14523176 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (high-iron and low-iron groups combined)
Number of subjects: 1657
Study 14523176 — intervention group
Group type: COMPARATOR
Intervention: No-added-iron group
Number of subjects: 1657
Study 11101069 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine plus didanosine
Number of subjects: 60
Study 11101069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine plus nevirapine
Number of subjects: 60
Study 8833713 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (bedtime delayed until 3 a.m.)
Number of subjects: 8
Study 8833713 — intervention group
Group type: COMPARATOR
Intervention: Reference night (normal sleep)
Number of subjects: 8
Study 1738926 — intervention group
Group type: EXPERIMENTAL
Intervention: ALG (Merieux) until serum creatinine was less than 300 mumol/L
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: No rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: Steroid-sensitive rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: Steroid-resistant rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: First rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: Second rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: Third rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: Patients free of rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: Patients with delayed graft function and sensitized patients
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: Patients with at least 1 rejection in the first 90 days
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: Patients with stable renal function
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: 1 year SCr for patients without rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: 1 year SCr for patients with steroid-sensitive rejection
Number of subjects: 110
Study 1738926 — intervention group
Group type: COMPARATOR
Intervention: 1 year SCr for patients with steroid-resistant rejection
Number of subjects: 110
Study 6325522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators (isosorbide dinitrate, minoxidil, enalapril or captopril)
Number of subjects: 46
Study 6325522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30502047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy (Group 1)
Number of subjects: 3
Study 30502047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (Group 2)
Number of subjects: 3
Study 30502047 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care vitamin K antagonist and DAPT (Group 3)
Number of subjects: 3
Study 28447159 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term adjunctive antiarrhythmic drug therapy with amiodarone (group A) for the first 3 months
Number of subjects: 230
Study 28447159 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy except for beta blockers (group B)
Number of subjects: 230
Study 28447159 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term adjunctive antiarrhythmic drug therapy with amiodarone (group A)
Number of subjects: 230
Study 27515716 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 2267
Study 27515716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) levels
Number of subjects: 2267
Study 27515716 — intervention group
Group type: COMPARATOR
Intervention: HbA1c of 5.7-6.4% (39-46mmol/mol)
Number of subjects: 2267
Study 27515716 — intervention group
Group type: COMPARATOR
Intervention: FPG of 5.5-6.9mmol/L
Number of subjects: 2267
Study 25060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (FF) 9.6 μg MDI
Number of subjects: 34
Study 25060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (FF) 2.4 μg MDI
Number of subjects: 34
Study 25060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (FF) 4.8 μg MDI
Number of subjects: 34
Study 25060541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Foradil (FA) 12 μg
Number of subjects: 34
Study 23209840 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol treatment (BACs of 0.048%)
Number of subjects: 56
Study 23209840 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol treatment (BACs of 0.082%)
Number of subjects: 56
Study 23209840 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol treatment (BACs of 0.10%)
Number of subjects: 56
Study 23209840 — intervention group
Group type: COMPARATOR
Intervention: Alcohol treatment (BACs of 0.00%)
Number of subjects: 56
Study 23209840 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspection Time (IT) test
Number of subjects: 56
Study 20833874 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (suture repair of the injured ligament(s) within the first week after injury, followed by a below‐the‐knee plaster cast for six weeks with full weight‐bearing)
Number of subjects: 51
Study 20833874 — intervention group
Group type: COMPARATOR
Intervention: Functional treatment (use of an Aircast ankle brace for three weeks)
Number of subjects: 51
Study 20833874 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 51
Study 20833874 — intervention group
Group type: COMPARATOR
Intervention: Functional treatment
Number of subjects: 51
Study 18768021 — intervention group
Group type: EXPERIMENTAL
Intervention: New manual toothbrush with modified shape
Number of subjects: 16
Study 18768021 — intervention group
Group type: COMPARATOR
Intervention: Traditionally shaped toothbrush
Number of subjects: 16
Study 16416642 — intervention group
Group type: EXPERIMENTAL
Intervention: Restylane 0.7 mL
Number of subjects: 8
Study 16416642 — intervention group
Group type: COMPARATOR
Intervention: Hylaform 1.0 mL
Number of subjects: 8
Study 12826972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (33.0 to 34.0 degrees C) combined with barbiturate coma
Number of subjects: 21
Study 12826972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia for <72 hours (group 1: mean 42.2 hours)
Number of subjects: 21
Study 12826972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia for >72 hours (group 2: mean 153.9 hours)
Number of subjects: 21
Study 12826972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia and barbiturate coma
Number of subjects: 21
Study 10530413 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenic HIV‐1 infected patients
Number of subjects: 88
Study 10530413 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-thrombocytopenic HIV‐1 infected patients
Number of subjects: 88
Study 10530413 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 88
Study 10530413 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune thrombocytopenic purpura (AITP) group
Number of subjects: 88
Study 10530413 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild thrombocytopenic group
Number of subjects: 88
Study 10530413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancytopenic patients
Number of subjects: 88
Study 8770739 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative guanethidine
Number of subjects: 71
Study 8770739 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 71
Study 2239757 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 40% medium-chain triglycerides and added L-carnitine
Number of subjects: 20
Study 2239757 — intervention group
Group type: COMPARATOR
Intervention: Formula with 40% medium-chain triglycerides without added L-carnitine
Number of subjects: 20
Study 110520 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 243
Study 110520 — intervention group
Group type: COMPARATOR
Intervention: Penicillin-V
Number of subjects: 243
Study 31037378 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 40
Study 31037378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31037378 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 40
Study 31444180 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based active surveillance protocol with standardised triggers for repeated biopsies and radical treatment
Number of subjects: 2000
Study 31444180 — intervention group
Group type: COMPARATOR
Intervention: Current practice surveillance
Number of subjects: 2000
Study 28650566 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of LNG-IUS (n=134)
Number of subjects: 267
Study 28650566 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUS (n=133)
Number of subjects: 267
Study 27509703 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment and aspiration of abscess cavity
Number of subjects: 0
Study 27509703 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment alone
Number of subjects: 0
Study 24090370 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization focusing on birth planning and hospital transport, community birth attendant training in problem recognition, and facility staff training in the management of obstetric and neonatal emergencies.
Number of subjects: 0
Study 24090370 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 0
Study 21943067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification advice (3-monthly)
Number of subjects: 4600
Study 21943067 — intervention group
Group type: COMPARATOR
Intervention: Less-intensive lifestyle modification advice (12-monthly; control group)
Number of subjects: 4600
Study 18280963 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate consultation with an oral and maxillofacial surgeon before surgery
Number of subjects: 0
Study 18280963 — intervention group
Group type: COMPARATOR
Intervention: Standard information provided just before surgery
Number of subjects: 0
Study 17161066 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (PCI)
Number of subjects: 365
Study 17161066 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 365
Study 12749435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (12.5 mg/d for the first 10 days of the cycle)
Number of subjects: 41
Study 12749435 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d)
Number of subjects: 41
Study 12749435 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/d)
Number of subjects: 41
Study 10886477 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoker stickers intervention
Number of subjects: 393
Study 10886477 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 393
Study 1331443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily for four weeks
Number of subjects: 100
Study 1331443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily for four weeks
Number of subjects: 100
Study 1331443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg once daily for six weeks
Number of subjects: 100
Study 1331443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1331443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 100
Study 3904570 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium 50 mg tid
Number of subjects: 100
Study 3904570 — intervention group
Group type: COMPARATOR
Intervention: matching placebo tid
Number of subjects: 100
Study 30476587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (n=16)
Number of subjects: 266
Study 30476587 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression-based overall score (n=16)
Number of subjects: 266
Study 30476587 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (placebo group, n=8)
Number of subjects: 266
Study 30078660 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg intravenous dexamethasone
Number of subjects: 164
Study 30078660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 25762016 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene (SP) tibial inserts
Number of subjects: 192
Study 25762016 — intervention group
Group type: EXPERIMENTAL
Intervention: XLP polyethylene liner
Number of subjects: 192
Study 22677231 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help program for depression (Deprexis)
Number of subjects: 0
Study 22677231 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study 20154055 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS/MAPS+
Number of subjects: 251
Study 20154055 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 251
Study 18664303 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg)
Number of subjects: 16
Study 18664303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15964709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiotherapy (RT) at 50.4 Gy
Number of subjects: 20
Study 15964709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiotherapy (RT) at 64.8 Gy
Number of subjects: 20
Study 15964709 — intervention group
Group type: COMPARATOR
Intervention: Cranial radiotherapy (RT)
Number of subjects: 20
Study 12118026 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (350 mg/m² intravenously for 90 minutes) alone
Number of subjects: 7
Study 12118026 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (100 mg/m²) with ketoconazole (200 mg orally for 2 days)
Number of subjects: 7
Study 12118026 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (350 mg/m²) alone
Number of subjects: 7
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lycopene intake
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cholesterol
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Study site
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Income level
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/ethnicity
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C consumption
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 111
Study 10203560 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise regression analysis
Number of subjects: 111
Study 8710065 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFNA (9 million IU intramuscular every other day for 6 months)
Number of subjects: 20
Study 8710065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1495453 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (oral administration)
Number of subjects: 12
Study 6365448 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta Lippes Loop
Number of subjects: 906
Study 6365448 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta TCu22OC
Number of subjects: 906
Study 6365448 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu22OC (non-sutured)
Number of subjects: 906
Study 6365448 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu22OC (sutured)
Number of subjects: 906
Study 6365448 — intervention group
Group type: EXPERIMENTAL
Intervention: All IUD models
Number of subjects: 906
Study 6365448 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta Loop
Number of subjects: 906
Study 6365448 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu22OC
Number of subjects: 906
Study 31961419 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (pancreatic drainage surgery within 6 weeks after randomization)
Number of subjects: 88
Study 31961419 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 88
Study 31961419 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy-first approach
Number of subjects: 88
Study 30277850 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month anti-inflammatory diet
Number of subjects: 20
Study 30138230 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) with modified Rankin Scale (mRS) as anchor
Number of subjects: 0
Study 30138230 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) with Stroke Impact Scale (SIS) as anchor
Number of subjects: 0
Study 30138230 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) for IGS <0.40 m/s with modified Rankin Scale (mRS) as anchor
Number of subjects: 0
Study 30138230 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) for IGS <0.40 m/s with Stroke Impact Scale (SIS) as anchor
Number of subjects: 0
Study 30138230 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) for IGS ≥0.40 m/s with modified Rankin Scale (mRS) as anchor
Number of subjects: 0
Study 30138230 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT) for IGS ≥0.40 m/s with Stroke Impact Scale (SIS) as anchor
Number of subjects: 0
Study 26511764 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry postponement intervention (30-minute period in the early evening)
Number of subjects: 361
Study 26511764 — intervention group
Group type: COMPARATOR
Intervention: Registration group (no intervention)
Number of subjects: 361
Study 26511764 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry postponement intervention
Number of subjects: 361
Study 23995813 — intervention group
Group type: EXPERIMENTAL
Intervention: Special physiotherapeutic training
Number of subjects: 46
Study 22954905 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 114
Study 22954905 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 114
Study 22954905 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 114
Study 22954905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 114
Study 22954905 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 114
Study 20571455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 138
Study 20571455 — intervention group
Group type: COMPARATOR
Intervention: Without tourniquet
Number of subjects: 138
Study 17327245 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (during pregnancy)
Number of subjects: 0
Study 17327245 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (during pregnancy)
Number of subjects: 0